29 July 2021Big PharmaAlex Baldwin

Is big pharma’s antidote to the COVID-19 waiver a viable alternative?

In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

AIPPI weighs in on COVID waiver

17 May 2021 The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.

Big Pharma

Under-pressure pharma groups release vaccine scale-up plan

25 May 2021 Several pharmaceutical organisations have joint-published a five-step plan to help provide more equitable access to COVID-19 vaccines that would avoid waiving IP rights.

Big Pharma

MPP signs first COVID-19 licensing deal over MSD’s molnupiravir

28 October 2021 UN-backed public health organisation The Medicine Patent Pool (MPP) has entered into a licence agreement with Merck Sharp & Dohme (MSD) and others to increase access to molnupiravir (MK-4482, EIDD-2801)—an investigational oral COVID-19 medicine—for low-and-middle-income countries (LMIC).

More on this story

Big Pharma

AIPPI weighs in on COVID waiver

Big Pharma

Under-pressure pharma groups release vaccine scale-up plan

25 May 2021 Several pharmaceutical organisations have joint-published a five-step plan to help provide more equitable access to COVID-19 vaccines that would avoid waiving IP rights.

Big Pharma

MPP signs first COVID-19 licensing deal over MSD’s molnupiravir

More on this story

Big Pharma

AIPPI weighs in on COVID waiver

Big Pharma

Under-pressure pharma groups release vaccine scale-up plan

25 May 2021 Several pharmaceutical organisations have joint-published a five-step plan to help provide more equitable access to COVID-19 vaccines that would avoid waiving IP rights.

Big Pharma

MPP signs first COVID-19 licensing deal over MSD’s molnupiravir